

France Head and Neck Cancer Market By Type (Diagnostic Methods, Treatment Type), By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F

Market Report | 2023-11-07 | 77 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

Report description:

France Head and Neck Cancer Market is anticipated to project impressive growth in the forecast period. Head and neck cancer constitutes a significant healthcare challenge globally, and France is no exception. The France Head and Neck Cancer market have witnessed substantial growth in recent years, driven by a confluence of factors ranging from advancements in medical technology to evolving treatment modalities and changing demographic patterns.

Key Market Drivers

Increasing Incidence Rates

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The escalating incidence of head and neck cancer in France presents both a challenge and an opportunity for the healthcare industry. As the number of diagnosed cases continues to rise, there is a significant potential for the Head and Neck Cancer market in France to expand.

With the increasing incidence of head and neck cancers, there is a growing need for early detection and diagnosis. This demand fuels investments in advanced diagnostic technologies and screening programs. Healthcare providers are prompted to adopt cutting-edge imaging techniques, molecular diagnostics, and other tools that facilitate the identification of cancers at earlier, more treatable stages.

A higher incidence of head and neck cancer naturally translates into an increased demand for treatment services. This surge in patient numbers propels growth in various aspects of cancer care, from surgery and radiation therapy to chemotherapy and emerging immunotherapies. Healthcare facilities respond by expanding their capabilities, leading to a broader and more robust market for cancer treatments.

The rising incidence rates create a fertile ground for pharmaceutical and biotech companies to invest in research and development. The quest for more effective and targeted therapies gains momentum as the market responds to the specific needs posed by the increasing diversity of head and neck cancer cases. This, in turn, contributes to the expansion of the market with the introduction of novel and more precise treatment options.

The surge in patient numbers creates a larger pool for clinical trials and research initiatives. Pharmaceutical companies, academic institutions, and healthcare organizations seize the opportunity to conduct studies that explore new therapeutic approaches, innovative drugs, and potential breakthroughs in the understanding of head and neck cancers. This not only advances scientific knowledge but also stimulates growth within the research and development sector.

The growing prevalence of head and neck cancer enhances the economic viability of healthcare facilities specializing in cancer care. Increased patient inflow allows these institutions to invest in state-of-the-art equipment, hire specialized medical professionals, and expand infrastructure. Consequently, this contributes to the overall growth of the healthcare industry in the context of head and neck cancer.

Technological Advancements in Diagnosis and Treatment

The landscape of healthcare is continually evolving, and nowhere is this more evident than in the field of head and neck cancer. In France, the convergence of cutting-edge technological advancements in diagnosis and treatment has not only revolutionized patient care but also sparked substantial growth in the Head and Neck Cancer market.

Technological strides in diagnostic imaging, molecular profiling, and genetic testing have transformed the landscape of early cancer detection. These advancements empower healthcare providers to identify head and neck cancers at earlier, more treatable stages. The implementation of high-resolution imaging modalities, such as positron emission tomography-computed tomography (PET-CT) scans, allows for precise localization and characterization of tumors, facilitating more targeted and effective treatment strategies.

The era of one-size-fits-all cancer treatments is giving way to personalized medicine. Technological advancements enable the identification of specific genetic mutations or biomarkers associated with head and neck cancers. This information allows healthcare professionals to tailor treatment plans to the unique molecular profile of each patient, optimizing therapeutic outcomes and minimizing side effects.

The incorporation of artificial intelligence and machine learning algorithms has significantly enhanced diagnostic accuracy and treatment planning. AI-powered tools can analyze vast datasets, aiding in the interpretation of complex medical images, identifying patterns, and predicting treatment responses. In the context of head and neck cancer, AI contributes to faster and more accurate diagnosis, improving overall patient outcomes.

Technological advancements in radiation therapy, such as intensity-modulated radiation therapy (IMRT) and proton therapy, enable more precise targeting of cancerous tissues while sparing surrounding healthy structures. These advancements result in enhanced treatment efficacy and reduced side effects, attracting both patients and healthcare providers towards adopting state-of-the-art radiation oncology solutions.

The development of immunotherapeutic approaches has ushered in a new era in cancer treatment. Technologies like immune checkpoint inhibitors and adoptive cell therapy harness the body's immune system to target and eliminate cancer cells. These groundbreaking therapies, often backed by genetic and molecular diagnostics, provide a novel and effective arsenal against head

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and neck cancers.

Immunotherapy Breakthroughs

In the dynamic landscape of cancer treatment, immunotherapy has emerged as a revolutionary force, transforming the way we combat malignancies. This is particularly true in the case of head and neck cancer, where breakthroughs in immunotherapy are not only reshaping patient outcomes but also propelling substantial growth in the France Head and Neck Cancer market.

Immunotherapy represents a paradigm shift in cancer treatment by harnessing the body's own immune system to recognize and attack cancer cells. In the context of head and neck cancer, where traditional treatments may face challenges, immunotherapy offers a promising avenue for improved therapeutic responses and enhanced patient survival rates.

One of the key factors fueling the growth of the Head and Neck Cancer market in France is the notable improvement in patient outcomes associated with immunotherapy. Studies have demonstrated that immunotherapeutic approaches, such as immune checkpoint inhibitors, can lead to higher response rates and longer survival, especially in recurrent or metastatic cases. This success has garnered increased attention from both healthcare providers and patients alike, driving the demand for these innovative treatments.

Immunotherapy has expanded the arsenal of treatment options available for head and neck cancer patients. As breakthrough drugs gain regulatory approvals, healthcare providers in France are incorporating these novel therapies into their treatment protocols. This diversification of treatment options not only improves patient care but also fosters market growth as pharmaceutical companies invest in research and development.

The field of immunotherapy is witnessing advancements in personalized medicine, wherein treatment approaches are tailored to the individual characteristics of each patient's cancer. Biomarker testing and molecular diagnostics play a crucial role in identifying patients who are most likely to benefit from specific immunotherapies. This precision medicine approach enhances the effectiveness of treatment and contributes to the market's expansion.

The momentum in immunotherapy research is driving an abundance of clinical trials aimed at exploring new drugs, combination therapies, and treatment strategies for head and neck cancer. The participation of France in these trials not only advances scientific knowledge but also positions the country at the forefront of innovative cancer care. The robust clinical trial landscape further stimulates growth in the Head and Neck Cancer market.

Patient Advocacy and Awareness

In the complex realm of healthcare, patient advocacy and awareness are becoming increasingly instrumental in shaping not only the patient experience but also the trajectory of entire disease markets. In France, the Head and Neck Cancer market is experiencing a transformative influence, driven by the proactive efforts of patient advocates and heightened awareness campaigns.

Patient advocacy groups and awareness campaigns have a profound impact on elevating public awareness about head and neck cancer in France. By disseminating information about risk factors, symptoms, and available resources, these initiatives contribute to early detection and diagnosis. As awareness increases, more individuals seek medical advice, leading to a higher number of diagnosed cases and a subsequent demand for related healthcare services.

Patient advocates play a crucial role in encouraging individuals to undergo regular screenings and seek prompt medical attention when experiencing potential symptoms of head and neck cancer. Timely diagnosis is paramount in improving treatment outcomes, and the advocacy efforts geared towards encouraging proactive healthcare-seeking behavior contribute to an increased demand for diagnostic services within the market.

Patient advocacy groups provide a platform for individuals affected by head and neck cancer to connect, share experiences, and access support networks. These communities not only empower patients and their families but also foster a sense of solidarity. By creating supportive environments, patient advocates contribute to improved mental health outcomes and overall well-being, indirectly influencing the growth of the Head and Neck Cancer market by encouraging ongoing engagement with healthcare services.

Heightened awareness campaigns emphasize the importance of early intervention and adherence to prescribed treatment plans. Patients who are well-informed about the significance of follow-up appointments, treatment compliance, and lifestyle modifications are more likely to actively participate in their care. This commitment to treatment fosters a conducive environment for the growth of the Head and Neck Cancer market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Patient advocacy groups often play a pivotal role in advocating for increased research funding, driving innovation in the field of head and neck cancer. By raising awareness about the need for continued research, these advocates contribute to the development of novel therapies, diagnostic tools, and treatment modalities. This, in turn, attracts investment and stimulates growth within the market.

Key Market Challenges

Late-stage Diagnosis and Limited Screening

A persistent challenge in the France Head and Neck Cancer market is the prevalence of late-stage diagnoses. Limited awareness and routine screening programs result in delayed detection, reducing the efficacy of treatment options. Overcoming this challenge requires comprehensive public health campaigns and targeted initiatives to encourage early detection practices.

Multifaceted Treatment Approaches

Head and neck cancers often necessitate a multidisciplinary approach involving surgery, radiation therapy, chemotherapy, and more recently, immunotherapy. Coordinating these diverse treatments poses a logistical challenge, requiring effective communication and collaboration among healthcare professionals. Streamlining treatment pathways and ensuring interdisciplinary coordination remains a challenge that impacts patient care.

Treatment-related Morbidity and Quality of Life

Aggressive treatment regimens, particularly for advanced head and neck cancers, can lead to significant treatment-related morbidity. Patients may experience speech and swallowing difficulties, nutritional challenges, and alterations in facial appearance. Balancing the need for effective treatment with preserving quality of life poses an ongoing challenge for healthcare providers.

Key Market Trends

Advancements in Immunotherapy

Immunotherapy, which harnesses the body's immune system to combat cancer, continues to be a focal point in head and neck cancer research. Upcoming trends in France's Head and Neck Cancer market include the development of novel immunotherapeutic agents, combination therapies, and refined strategies for personalized immunotherapy. The aim is to enhance treatment efficacy, expand patient eligibility, and minimize adverse effects.

Precision Medicine and Targeted Therapies

The era of precision medicine is unfolding in the Head and Neck Cancer market, with a growing emphasis on targeted therapies tailored to individual patient profiles. Biomarker-driven treatment approaches, genetic testing, and molecular diagnostics are anticipated to become more commonplace, allowing for more effective and personalized interventions.

Integration of Artificial Intelligence (AI)

AI and machine learning are becoming integral components in cancer diagnosis, treatment planning, and research. In the Head and Neck Cancer market in France, AI applications are expected to enhance the analysis of medical images, aid in early detection, and provide predictive modeling for treatment responses. This trend is poised to improve diagnostic accuracy and treatment outcomes.

Segmental Insights

Disease Indication Insights

Based on Disease Indication, Lip and Oral Cavity Cancer is poised to dominate as a prominent disease indication in the Head and Neck Cancer Market in France for several compelling reasons. Firstly, the rising prevalence of risk factors such as tobacco use and excessive alcohol consumption in the country contributes significantly to the incidence of oral cancers. Additionally, increasing awareness about the importance of early detection and advancements in diagnostic technologies have led to a higher rate of diagnosis for lip and oral cavity cancers. Moreover, the evolving landscape of personalized medicine and targeted therapies has opened up new avenues for effective treatment modalities, enhancing the overall outlook for patients with this specific indication. The convergence of these factors positions Lip and Oral Cavity Cancer as a focal point in the French Head and Neck Cancer Market, underscoring the need for strategic investments, research, and innovative solutions to address this growing healthcare concern.

End User Insights

Based on End User, Hospitals are set to emerge as the dominant end user in the Head and Neck Cancer Market in France due to several key factors. Firstly, hospitals serve as comprehensive healthcare hubs equipped with state-of-the-art diagnostic facilities,

specialized medical professionals, and advanced treatment modalities, making them the primary choice for patients seeking comprehensive care for head and neck cancers. The complex nature of head and neck cancer treatments often requires a multidisciplinary approach, and hospitals are well-positioned to provide integrated services, including surgery, radiation therapy, and chemotherapy. Furthermore, the increasing prevalence of head and neck cancers necessitates a centralized and efficient healthcare infrastructure, which hospitals inherently possess. Collaboration between hospitals and research institutions fosters continuous advancements in treatment protocols and encourages clinical trials, solidifying hospitals as pivotal players in the delivery of cutting-edge care for head and neck cancer patients in the French market.

Regional Insights

Northern France is poised to dominate the Head and Neck Cancer Market in the country for various strategic reasons. Firstly, the region's robust healthcare infrastructure, marked by leading medical centers and research institutions, positions it as a hub for advanced diagnostics, treatment, and research related to head and neck cancers. Additionally, Northern France's proactive approach towards healthcare investments and technological advancements enhances its capacity to adopt and implement cutting-edge therapies effectively. Geographical accessibility and well-developed transportation networks in this region facilitate the seamless delivery of healthcare services, attracting patients from surrounding areas. Furthermore, the concentration of skilled healthcare professionals and collaborative initiatives between public and private entities create a conducive environment for the development and implementation of innovative solutions for head and neck cancer patients. The confluence of these factors establishes Northern France as a frontrunner in shaping the landscape of the Head and Neck Cancer Market in the country.

Key Market Players

Eli Lilly and Company

Bristol Myers Squibb France

Sanofi SA/France

Merck & Co., Inc.

Pfizer Inc.

AbbVie SAS

Bayer AG

Sun Pharmaceuticals France

Teva Pharmaceutical Industries Limited

AstraZeneca France

Report Scope:

In this report, the France Head and Neck Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□ France Head and Neck Cancer Market, By Type:

o□ Diagnostic Methods

o□ Treatment Type

□□ France Head and Neck Cancer Market, By Disease Indication:

o□ Lip and Oral Cavity Cancer

o□ Laryngeal Cancer

o□ Oropharyngeal Cancer

o□ Salivary Gland Cancer

o□ Nasopharyngeal Cancer

o□ Hypopharyngeal Cancer

□□ France Head and Neck Cancer Market, By Route of Administration:

o□ Injectable

o□ Oral

□□ France Head and Neck Cancer Market, By Therapeutic Class:

o□ PD Inhibitors

o□ EGFR Inhibitors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Microtubule Inhibitors

- France Head and Neck Cancer Market, By End User:

- o Hospitals

- o Specialty Clinics

- o Ambulatory Surgical Centers

- o Others

- France Head and Neck Cancer Market, By Region:

- o Northern France

- o Southern France

- o Western France

- o Central France

- o Eastern France

- o Southwestern France

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the France Head and Neck Cancer Market.

Available Customizations:

France Head and Neck Cancer market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

- 1. Product Overview

- 1.1. Market Definition

- 1.2. Scope of the Market

- 1.2.1. Markets Covered

- 1.2.2. Years Considered for Study

- 1.2.3. Key Market Segmentations

- 2. Research Methodology

- 2.1. Objective of the Study

- 2.2. Baseline Methodology

- 2.3. Key Industry Partners

- 2.4. Major Association and Secondary Sources

- 2.5. Forecasting Methodology

- 2.6. Data Triangulation & Validation

- 2.7. Assumptions and Limitations

- 3. Executive Summary

- 3.1. Overview of the Market

- 3.2. Overview of Key Market Segmentations

- 3.3. Overview of Key Market Players

- 3.4. Overview of Key Regions/Countries

- 3.5. Overview of Market Drivers, Challenges, Trends

- 4. Voice of Customer

- 5. France Head and Neck Cancer Market Outlook

- 5.1. Market Size & Forecast

- 5.1.1. By Value

- 5.2. Market Share & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.1.□By Type (Diagnostic Methods, Treatment Type)
 - 5.2.1.1.□By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
 - 5.2.1.2.□By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
- 5.2.2.□By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
- 5.2.3.□By Route of Administration (Injectable, Oral)
- 5.2.4.□By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
- 5.2.5.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 5.2.6.□By Region
- 5.2.7.□By Company (2022)
- 5.3.□Market Map
 - 5.3.1. By Type
 - 5.3.2. By Disease Indication
 - 5.3.3. By Route of Administration
 - 5.3.4. By Therapeutic Class
 - 5.3.5. By End User
 - 5.3.6. By Region
- 6.□Northern France Head and Neck Cancer Market Outlook
 - 6.1.□Market Size & Forecast□
 - 6.1.1.□By Value
 - 6.2.□Market Share & Forecast
 - 6.2.1.□By Type (Diagnostic Methods, Treatment Type)
 - 6.2.1.1.□By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
 - 6.2.1.2.□By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
 - 6.2.2.□By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
 - 6.2.3.□By Route of Administration (Injectable, Oral)
 - 6.2.4.□By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
 - 6.2.5.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 7.□Southern France Head and Neck Cancer Market Outlook
 - 7.1.□Market Size & Forecast□
 - 7.1.1.□By Value
 - 7.2.□Market Share & Forecast
 - 7.2.1.□By Type (Diagnostic Methods, Treatment Type)
 - 7.2.1.1.□By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
 - 7.2.1.2.□By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
 - 7.2.2.□By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
 - 7.2.3.□By Route of Administration (Injectable, Oral)
 - 7.2.4.□By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
 - 7.2.5.□By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 8.□Western France Head and Neck Cancer Market Outlook
 - 8.1.□Market Size & Forecast□
 - 8.1.1.□By Value
 - 8.2.□Market Share & Forecast
 - 8.2.1.□By Type (Diagnostic Methods, Treatment Type)
 - 8.2.1.1.□By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.1.2. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
- 8.2.2. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
- 8.2.3. By Route of Administration (Injectable, Oral)
- 8.2.4. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
- 8.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 9. Central France Head and Neck Cancer Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Type (Diagnostic Methods, Treatment Type)
 - 9.2.1.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
 - 9.2.1.2. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
 - 9.2.2. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
 - 9.2.3. By Route of Administration (Injectable, Oral)
 - 9.2.4. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
 - 9.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 10. Eastern France Head and Neck Cancer Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Type (Diagnostic Methods, Treatment Type)
 - 10.2.1.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
 - 10.2.1.2. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
 - 10.2.2. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
 - 10.2.3. By Route of Administration (Injectable, Oral)
 - 10.2.4. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
 - 10.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 11. Southwestern France Head and Neck Cancer Market Outlook
 - 11.1. Market Size & Forecast
 - 11.1.1. By Value
 - 11.2. Market Share & Forecast
 - 11.2.1. By Type (Diagnostic Methods, Treatment Type)
 - 11.2.1.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)
 - 11.2.1.2. By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)
 - 11.2.2. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)
 - 11.2.3. By Route of Administration (Injectable, Oral)
 - 11.2.4. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)
 - 11.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 12. Market Dynamics
 - 12.1. Drivers
 - 12.2. Challenges
- 13. Market Trends & Developments
 - 13.1. Recent Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2.□Mergers & Acquisitions
- 13.3.□Product Launches
- 14.□Policy & Regulatory Landscape
- 15.□Porter's Five Forces Analysis
- 15.1.□Competition in the Industry
- 15.2.□Potential of New Entrants
- 15.3.□Power of Suppliers
- 15.4.□Power of Customers
- 15.5.□Threat of Substitute Products
- 16.□France Economic Profile
- 17.□Competitive Landscape
- 17.1.□Business Overview
- 17.2.□Product Offerings
- 17.3.□Recent Developments
- 17.4.□Financials (As Reported)
- 17.5.□Key Personnel
- 17.6.□SWOT Analysis
- 17.6.1.□Eli Lilly and Company
- 17.6.2.□Bristol Myers Squibb France
- 17.6.3.□Sanofi SA/France
- 17.6.4.□Merck & Co., Inc.
- 17.6.5.□Pfizer Inc.
- 17.6.6.□AbbVie SAS
- 17.6.7.□Bayer AG
- 17.6.8.□Sun Pharmaceuticals France
- 17.6.9.□Teva Pharmaceutical Industries Limited
- 17.6.10.□ AstraZeneca France
- 18.□Strategic Recommendations

France Head and Neck Cancer Market By Type (Diagnostic Methods, Treatment Type), By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer), By Route of Administration (Injectable, Oral), By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F

Market Report | 2023-11-07 | 77 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.
☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>